EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudie

Efficacy and safety of doxorubicin–ifosfamide versus gemcitabine–docetaxel as first‐line therapy in advanced nonuterine leiomyosarcoma: A multicenter real‐world study

Salih Tunbekici iD, Gokhan Sahin, Haydar Cagatay Yuksel, Caner Acar, Imge Akın, Hasan Aslanhan, Mert Iscı, Ceren Kabaoglu, Hamit Bal, Abdullah Sakin, Alper Coskun, Mehmet Sıddık Dilek und 35 weitere

International Journal of Cancer · 15.03.2026 · 158 (6) · 1703-1712

DOI: 10.1002/ijc.70212 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Cancer, online erschienen am 28.10.2025. Verfasst von Salih Tunbekici und 46 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Ege University Medical Faculty, Izmir, Turkey. Hauptthemen laut MEDLINE: Leiomyosarcoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nonuterine leiomyosarcoma (NU‐LMS) is a rare and biologically distinct subtype of soft tissue sarcoma (STS) with clinical behavior differing from that of uterine leiomyosarcoma. In advanced or metastatic STS, immunotherapy has demonstrated only modest activity, and chemotherapy remains the cornerstone of treatment. However, there is a persistent unmet need for more effective and better‐tolerated options in this population. This multicenter, retrospective study included 150 patients with histologically confirmed metastatic NU‐LMS who received first‐line doxorubicin–ifosfamide (AI) or gemcitabine–docetaxel (GD) at 26 oncology centers in Turkey between 2010 and 2024. The primary endpoint was overall survival (OS). Survival was analyzed using Kaplan–Meier estimates and Cox proportional hazards models. Of 150 patients, 79 received AI and 71 received GD. Median OS for the entire cohort was 21.0 months. Median OS was 22.0 months with AI and 19.1 months with GD ( p = .18), median progression‐free survival was 7.3 versus 6.1 months ( p = .66), and overall response rate was 25.3% versus 29.6% ( p = .58), indicating no statistically significant differences in efficacy between the two regimens. Hematologic toxicities were less frequent with GD. AI and GD demonstrated comparable efficacy as first‐line regimens for advanced or metastatic NU‐LMS, with fewer hematologic toxicities observed for GD. Tumor location may have prognostic implications. These findings support individualized treatment selection and highlight the need for prospective studies in this rare and understudied sarcoma subtype, while the recent LMS‐04 trial underscores the importance of future comparisons with doxorubicin–trabectedin to further refine first‐line strategies in LMS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LeiomyosarcomaAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleGemcitabineDocetaxelDoxorubicinMiddle AgedDeoxycytidineRetrospective StudiesAgedMaleAdultIfosfamideAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

doxorubicin–ifosfamidegemcitabine–docetaxelmetastatic soft tissue sarcomanonuterine leiomyosarcomareal‐world study

Substanzen

GemcitabineDocetaxelDoxorubicinDeoxycytidineIfosfamide

Autor:innen und Institutionen

  • Department of Medical Oncology, Ege University Medical Faculty, Izmir, Turkey.
  • Department of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science University, Cevizli, Istanbul, Turkey.
  • Department of Medical Oncology, Medipol Bahçelievler Hospital, Istanbul Medipol University, Istanbul, Turkey.
  • Department of Medical Oncology, Uludağ University, Bursa, Turkey.
  • Department of Medical Oncology, Medical School, Dicle University, Diyarbakir, Turkey.
  • Department of Medical Oncology, Yuzuncu Yil University Faculty of Medicine, Van, Turkey.

ORCID-Profile: Salih Tunbekici, Elif Sahin

Zitieren

APA

Tunbekici, S., Sahin, G., Yuksel, H. C., Acar, C., Akın, I., Aslanhan, H., Iscı, M., Kabaoglu, C., Bal, H., Sakin, A., Coskun, A., Dilek, M. S., Kara, M., Solmaz, A., Zin, E., Terzi, A., Kus, F., Kus, I. K., Arık, Z., …, & Gursoy, P. (2026). Efficacy and safety of doxorubicin–ifosfamide versus gemcitabine–docetaxel as first‐line therapy in advanced nonuterine leiomyosarcoma: A multicenter real‐world study. International Journal of Cancer, 158(6), 1703-1712. https://doi.org/10.1002/ijc.70212

Vancouver

Tunbekici S, Sahin G, Yuksel HC, Acar C, Akın I, Aslanhan H, et al. Efficacy and safety of doxorubicin–ifosfamide versus gemcitabine–docetaxel as first‐line therapy in advanced nonuterine leiomyosarcoma: A multicenter real‐world study. International Journal of Cancer. 2026;158(6):1703-1712. doi:10.1002/ijc.70212

BibTeX
@article{Tunbekici2026,
  author = {Tunbekici, Salih and Sahin, Gokhan and Yuksel, Haydar Cagatay and Acar, Caner and Akın, Imge and Aslanhan, Hasan and Iscı, Mert and Kabaoglu, Ceren and Bal, Hamit and Sakin, Abdullah and Coskun, Alper and Dilek, Mehmet Sıddık and Kara, Mahmut and Solmaz, Ali and Zin, Evrican and Terzi, Aytac and Kus, Fatih and Kus, Ilgın Koc and Arık, Zafer and Aytac, Ali and Demirkıran, Özge and Demir, Bilgin and Yesil, Havva and Biter, Sedat and Koseci, Tolga and Bayram, Ertugrul and Unsal, Ahmet and Sevınc, Alper and Ozaskın, Duygu and Baykara, Meltem and Unlu, Ahmet and Kus, Arıf and Karacin, Cengiz and Uyar, Galip Can and Sutcuoglu, Osman and Kaplan, Esmanur and Sakalar, Teoman and Sahin, Elif and Emin, Gamze and Yıldırım, Atilla and Mordag, Ceren and Ugurlu, Irem and Hacıbekiroglu, Ilhan and Tunbekici, Ibrahim and Sanli, Ulus Ali and Goker, Erdem and Gursoy, Pınar},
  title = {Efficacy and safety of doxorubicin–ifosfamide versus gemcitabine–docetaxel as first‐line therapy in advanced nonuterine leiomyosarcoma: A multicenter real‐world study},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {158},
  number = {6},
  pages = {1703--1712},
  doi = {10.1002/ijc.70212}
}
Kostenlos starten →